Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bayer taps Roche for new CEO
by Alex Scott
February 24, 2023
| A version of this story appeared in
Volume 101, Issue 7
Credit: Bayer
Bill Anderson
Bayer has appointed Bill Anderson, a senior executive with Roche and former CEO of Genentech, its chief executive effective June 1. Anderson replaces Werner Baumann, whose term had been due to run until April 2024. Baumann has had a torrid few years as CEO. His 2018 acquisition of Monsanto exposed Bayer to thousands of lawsuits claiming that its leading product, Roundup, causes cancer. In addition, Bayer’s drug development pipeline has underwhelmed some investors.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X